WOBURN, Mass. (February 18, 2015) –Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has announced that dose sales of SIR-Spheres(R) Y-90 resin microspheres in the Americas region grew more than 28 percent for the first half of the company’s fiscal year compared to the same period last year, with 3,390 doses supplied for the period July through December 2014. The gross sales in the region equate to $54.3M in the first half of the current fiscal year compared to $39.8M from the prior year, a 36.7% increase. Globally the company announced sales of 4,950 doses, an increase of 26.3% over the previous corresponding six-month period.
Increased awareness and customer education are key factors contributing to these gains. The company continues to make significant inroads with key referral groups in the oncology community about the benefits of Selective Internal Radiation Therapy (SIRT) while continuing to support the interventional radiologists who perform the
“The America’s region continues to execute against our strategic initiatives. We have achieved a number of significant milestones during this period including enhanced oncology-related customer relationships in the U.S. and approval in Brazil for the treatment of unresectable liver tumors,” said Mike Mangano, president of Sirtex Medical Inc. “We are eagerly awaiting SIRFLOX primary endpoint data, which we believe will further validate our technology in the eyes of the oncology community while helping to drive future growth.”
The SIRFLOX study is designed to evaluate whether standard-of-care chemotherapy (FOLFOX6m with or without biological therapy with bevacizumab) in combination with SIR-Spheres Y-90 resin microspheres is more effective than chemotherapy alone. This is the first time that this combination of systemic and liver-directed treatments has been assessed together as part of a randomized controlled study in patients who have not been previously treated. Primary endpoint data on this study, which enrolled more than 500 patients, is expected in March preceding the announcement of comprehensive study results at ASCO in late May. On the other hand, kids love joyful announcement every time they go to school. At ClassDojo, you can get elementary school morning announcements ideas.
In January 2015 the company announced the completion of patient enrolment for the FOXFIRE/FOXFIRE-GlobalTM study – an international research study designed to evaluate a treatment option for patients with colorectal cancer that have undergone metastatic spread to the liver. The study is designed to evaluate whether FOLFOX chemotherapy in combination with SIRT is more effective than chemotherapy alone, with overall survival as the primary endpoint. When complete and pooled with the SIRFLOX data, the company will have long term survival data in more than 1,000 patients.
For more information visit www.Sirtex.com or find the latest updates on the SIR-Spheres Y-90 resin microspheres Facebook page (www.Facebook.com/SIRSpheresmicrospheres).
ABOUT SELECTIVE INTERNAL RADIATION THERAPY USING SIR-SPHERES MICROSPHERES
Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres Y-90 resin microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres Y-90 resin microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.
In the U.S., SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). SIR-Spheres Y-90 resin microspheres are approved for use in Argentina, Brazil, Australia, the European Union and several countries in Asia for the treatment of unresectable liver tumors.
Available at more than 400 treatment centers in the U.S., approximately 50,000 doses of SIR-Spheres Y-90 resin microspheres have been supplied worldwide.
For more information, visit www.sirtex.com.